Depomed submits Proquin XR
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Depomed files its once-daily, extended-release ciprofloxacin formulation Proquin XR for treatment of uncomplicated urinary tract infections, the firm announces July 20. The NDA is based on a single Phase III trial in 1,037 patients comparing a three-day course of Proquin XR to three days of twice-daily immediate release ciprofloxacin (Bayer's Cipro). The study showed an eradication rate of 93.4% for Proquin XR compared to 89.6% for Cipro. Depomed will highlight fewer gastrointestinal side effects; in the clinical trial Proquin patients had "five-fold fewer complaints of nausea and seven-fold fewer cases of diarrhea." Depomed's Gastric Retention technology provides for "preferential absorption in the upper intestine." The company is "in discussions with potential marketing partners" and "evaluating the opportunity to co-promote the product in certain markets"...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.